| Summary: | The lutein-containing vitamin-mineral complex Retinorm, developed on the basis of the formula AREDS 2, with an optimal content of vitamins and minerals involved in antioxidant protection, is a potentially promising ophthalmic geroprotector.Purpose: to evaluate the effectiveness of vitamin-mineral complex “Retinorm” in patients with the dry form of AMD and accelerated pace of aging.Patients and Methods. The study involved 40 patients with a dry form of AMD (stage 2.3 according to AREDS classification) with an accelerated rate of aging (biological age of patients was measured by the method of Tokar, 1990). Gender distribution: men — 15 (37.5 %), women — 25 (62.5 %). The mean age of patients was 67.3 ± 6.8 years. Patients were divided into 2 groups. Patients of the study group (n = 20) were assigned “Retinorm” 1 capsule 3 times a day for 16 weeks. Patients of the control group (n = 20) were treated with “Lutein Forte” 1 capsule 2 times a day for 16 weeks. Visometry, perimetry, optical coherence tomography of the macular zone, measurement of biological age at the beginning of the study, at 2 and 4 months of the study, the tolerability of treatment in patients with a dry form of age — related macular degeneration on the background of taking dietary supplements-vitamin and mineral complexes with lutein and zeaxanthin.Results and discussion. As a result of treatment, there were the positive dynamics in terms of visometry and perimetry in the main and control groups. There were no negative dynamics of the indicators of thickness of the retina (in the area of the fovea), and increased macular volume in the main group. In the control group there was a weak tendency to the growth of these indicators. We found a significant positive effect of Retinol on the biological age of patients to 4 months of therapy. It allows to consider the drug as a promising ophthalmoscopy an agent. The results of the study showed the effectiveness of the inclusion of “Retinorm” in patients with the dry form of AMD. The proven geroprotective effect of “Retinorm” with good tolerability of treatment and the absence of side effects from all organ systems with a long term of administration allows us to recommend it for wide use in patients with a dry form of age-related macular degeneration, including patients with an accelerated rate of aging.
|
|---|
